Back to Search Start Over

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.

Authors :
Macedo, Thais Rodrigues
de Queiroz, Genilson Fernandes
Casagrande, Thaís Andrade Costa
Alexandre, Pâmela Almeida
Brandão, Paulo Eduardo
Fukumasu, Heidge
Melo, Samanta Rios
Dagli, Maria Lucia Zaidan
Pinto, Ana Carolina B. C. Fonseca
Matera, Julia Maria
Source :
Cells (2073-4409). Mar2022, Vol. 11 Issue 3, p571-N.PAG. 1p.
Publication Year :
2022

Abstract

Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20734409
Volume :
11
Issue :
3
Database :
Academic Search Index
Journal :
Cells (2073-4409)
Publication Type :
Academic Journal
Accession number :
155243057
Full Text :
https://doi.org/10.3390/cells11030571